Treatment with TaxAC superior to TC in pooled analysis of women with resected high-risk HER2-negative early breast cancer.
With 5-year follow-up, local surgery followed by systemic therapy associated with significant improvement in OS vs initial systemic therapy with local therapy for localized progression in patients with MBC at presentation.
Phase Ib trial of combination therapy with atezolizumab and nab-paclitaxel showed a safety profile similar to each agent alone and produced durable responses in patients with mTNBC.
Phase III investigation of neoadjuvant T-DM1 plus pertuzumab showed a favorable safety profile but lower clinical response rate compared with chemotherapy with trastuzumab plus pertuzumab in HER2-positive early breast cancer.
Addition of pertuzumab to trastuzumab and capecitabine improved median OS by 8 months in patients with HER2-positive metastatic breast cancer who previously progressed during/after trastuzumab-based therapy but did not meet the primary endpoint of the study.
Palbociclib + letrozole achieved longest improvement in PFS seen to date for frontline treatment of ER+/HER2- advanced breast cancer.
Abemaciclib monotherapy was active in patients with heavily pretreated HR+/HER2- MBC and showed no new safety signals.
Here are the breast cancer abstracts that I am most interested in hearing about at this year’s ASCO annual meeting.
Sara Hurvitz, MD, FACP, and Tiffany A. Traina, MD, provide their expert analysis of key breast cancer presentations from the 2016 ASCO Annual Meeting in Chicago.
This study conducted by the Canadian Cancer Trials Group is the first to show that extending aromatase inhibitor therapy beyond 5 years reduces the risk of disease recurrence.
In this downloadable slideset, Sara Hurvitz, MD, FACP, and Tiffany A. Traina, MD, review important presentations in breast cancer from the 2016 ASCO meeting in Chicago.